What A Cholesterol Reading Actually Measures — And What It Misses
Millions of men walk out of their doctor's office every year having been told their cholesterol is fine. Some of them are on statins that have brought the number down. And some of those same men will still develop significant arterial disease. This post explains why — and what a cholesterol reading actually tells you versus what it does not.
What Is Cholesterol And Why Does The Body Make It
Cholesterol is a waxy, fat-like substance produced naturally by the liver and found in every cell of the body. Despite its reputation, cholesterol is not inherently dangerous. It is essential. The body uses it to build cell membranes, produce hormones including testosterone and oestrogen, synthesise vitamin D, and manufacture bile acids that aid in digestion.[1]
The problem is not cholesterol itself. The problem is when cholesterol levels become elevated and interact with damaged arterial walls in ways that contribute to plaque formation — a process known as atherosclerosis.[2]
The body cannot survive without cholesterol. The issue is not whether cholesterol exists in your blood — it always will — but what form it takes, how much of it there is, and what condition your arterial walls are in when it circulates past them.
What The Standard Cholesterol Test Measures
A standard lipid panel — the blood test most doctors order — measures four things: total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Understanding what each of these is actually measuring matters more than most people realise.[3]
Total cholesterol is the combined measurement of all cholesterol types in your blood. On its own it is a blunt instrument. Two people with identical total cholesterol readings can have very different cardiovascular risk profiles depending on how that cholesterol is distributed between LDL and HDL.
LDL cholesterol — often called "bad" cholesterol — is the lipoprotein that carries cholesterol from the liver to the body's cells. When LDL levels are elevated and arterial walls are damaged or inflamed, LDL particles can penetrate the arterial wall, become oxidised, and trigger the inflammatory process that begins plaque formation.[4]
HDL cholesterol — often called "good" cholesterol — is the lipoprotein that carries cholesterol back from the body to the liver for removal. Higher HDL is generally associated with lower cardiovascular risk because it performs a reverse transport function.[5]
Triglycerides are a type of fat found in the blood. Elevated triglycerides are associated with increased cardiovascular risk and are often elevated in people who consume excess sugar, refined carbohydrates, or alcohol.[6]
The Difference Between LDL Quantity And LDL Particle Size
This is where standard cholesterol testing begins to show its limitations. Your lipid panel tells you how much LDL cholesterol is present in your blood. It does not tell you what size those LDL particles are — and particle size matters significantly.[7]
LDL particles come in different sizes. Large, buoyant LDL particles are relatively benign. Small, dense LDL particles are more dangerous because they are better able to penetrate arterial walls, are more susceptible to oxidation, and are more likely to contribute to plaque formation.[8]
Two people can have an identical LDL reading of 120 mg/dL. One might have predominantly large buoyant particles with lower actual risk. The other might have predominantly small dense particles with significantly higher risk. A standard lipid panel cannot tell the difference.
More advanced testing — including LDL particle number tests (LDL-P) and apolipoprotein B (ApoB) measurements — provide a more accurate picture of actual arterial risk than the standard LDL number alone.[9] These tests are not yet universally offered but are increasingly available on request.
What A Normal Cholesterol Reading Does Not Rule Out
This is the most important point in this article. A normal cholesterol reading — even a well-managed one maintained with statins — does not mean your arteries are clear.
Arterial plaque can develop and accumulate even in people with cholesterol levels that fall within the normal range. The process of atherosclerosis is influenced by cholesterol levels, but it is also influenced by inflammation, endothelial damage, oxidative stress, blood pressure, blood sugar levels, smoking history, and genetic factors. Cholesterol is one variable in a complex process — not the only one.[10]
This is demonstrated clearly by coronary calcium scoring — a non-invasive CT scan that measures the amount of calcified plaque in the coronary arteries. Research consistently shows that a meaningful proportion of people with normal cholesterol levels have significant calcium scores, indicating established arterial disease that their lipid panel never flagged.[11]
- Whether plaque has already formed inside your arterial walls
- The size and density of your LDL particles
- The condition of your endothelium — the inner lining of your blood vessels
- Your level of arterial inflammation independent of cholesterol
- How much calcified plaque is present in your coronary arteries
- Your overall cardiovascular risk when combined with other factors
What Statins Do — And What They Don't
Statins are among the most widely prescribed medications in the world and their evidence base for reducing cardiovascular events is substantial.[12] They work by inhibiting an enzyme in the liver called HMG-CoA reductase, which plays a central role in cholesterol production. The result is a reduction in circulating LDL cholesterol.
What statins do well is lower the number on your lipid panel. They also have some anti-inflammatory properties that may contribute to their cardiovascular benefit beyond cholesterol reduction alone.[13]
What statins do not do is dissolve existing plaque, repair arterial walls that have already been damaged, restore endothelial function that has already declined, or address the other contributors to arterial disease that exist independently of cholesterol levels.
This is why some men on statins for years still develop cardiovascular disease. The medication did its job. But the job the medication was designed to do is not the same as comprehensively addressing arterial health.
The Role Of The Endothelium In Cholesterol And Plaque
The endothelium is the thin layer of cells that lines the interior of every blood vessel in the body. It is not passive. It is metabolically active — producing compounds that regulate blood vessel tone, blood clotting, inflammation, and the passage of substances in and out of the bloodstream.[14]
When the endothelium is healthy and functioning well, LDL cholesterol circulates past without infiltrating the arterial wall. When the endothelium is damaged — by high blood pressure, elevated blood sugar, smoking, inflammation, or oxidative stress — LDL particles can penetrate the wall more readily, where they become oxidised and trigger the inflammatory cascade that leads to plaque formation.[15]
This is why endothelial health is increasingly understood by cardiovascular researchers as the central factor in arterial disease — not cholesterol in isolation. Two people with the same LDL level will have very different outcomes depending on the integrity of their endothelium.[16]
Nitric oxide — produced by healthy endothelial cells — plays a critical role in keeping blood vessels flexible, reducing inflammation, and preventing LDL particles from adhering to arterial walls.[17] Declining nitric oxide production is one of the earliest signs of endothelial dysfunction and is associated with increased arterial disease risk independent of cholesterol levels.
Additional Markers Worth Discussing With Your Doctor
For a more complete picture of cardiovascular risk beyond the standard lipid panel, the following markers are increasingly discussed in cardiovascular research and may be worth raising with your doctor depending on your risk profile:[18]
- ApoB — A more precise measure of atherogenic particle number than LDL cholesterol alone
- Lp(a) — A genetic risk factor for cardiovascular disease independent of standard cholesterol levels
- hs-CRP — High-sensitivity C-reactive protein, a marker of arterial inflammation
- Coronary Calcium Score (CAC) — Directly measures calcified plaque in the coronary arteries
- Homocysteine — An amino acid associated with endothelial damage when elevated
- Fasting insulin — Elevated levels indicate metabolic dysfunction linked to arterial risk
When To Speak To Your Doctor
If your cholesterol is being managed with a statin and your numbers are within range, that is a positive step. But it is worth asking your doctor for a broader conversation about your overall cardiovascular risk profile — not just the number on your lipid panel.
Questions worth raising include whether additional markers like ApoB or hs-CRP might be relevant for your situation, whether a coronary calcium score would provide useful information given your age and risk factors, and what lifestyle factors alongside medication are most relevant to your arterial health.
Cholesterol management is one important piece of cardiovascular health. It is not the only piece, and a managed cholesterol number is not the same as a clean bill of arterial health.
The information in this post is intended for general educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making any changes to your health management or treatment plan.
- Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nature Reviews Molecular Cell Biology. 2020;21(4):225–245. doi:10.1038/s41580-019-0190-7
- Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nature Reviews Disease Primers. 2019;5(1):56. doi:10.1038/s41572-019-0106-z
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285–e350. doi:10.1016/j.jacc.2018.11.003
- Tabas I, García-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. Journal of Cell Biology. 2015;209(1):13–22. doi:10.1083/jcb.201412052
- Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nature Reviews Immunology. 2015;15(2):104–116. doi:10.1038/nri3793
- Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2011;123(20):2292–2333. doi:10.1161/CIR.0b013e3182160726
- Superko HR, Gadesam RR. Is it LDL particle size or number that correlates with risk for cardiovascular disease? Current Atherosclerosis Reports. 2008;10(5):377–385. doi:10.1007/s11883-008-0059-2
- Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260(13):1917–1921. doi:10.1001/jama.1988.03410130125039
- Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes. 2011;4(3):337–345. doi:10.1161/CIRCOUTCOMES.110.959247
- Toth PP, Thanassoulis G, Williams K, et al. The rationale for combination lipid therapy. Journal of Clinical Lipidology. 2014;8(3):S1–S3. doi:10.1016/j.jacl.2014.02.008
- Blaha MJ, Mortensen MB, Kianoush S, et al. Coronary artery calcium scoring. JACC: Cardiovascular Imaging. 2017;10(8):923–937. doi:10.1016/j.jcmg.2017.05.007
- Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi:10.1016/S0140-6736(10)61350-5
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine. 2008;359(21):2195–2207. doi:10.1056/NEJMoa0807646
- Félétou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder. American Journal of Physiology — Heart and Circulatory Physiology. 2006;291(3):H985–H1002. doi:10.1152/ajpheart.00292.2006
- Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III27–32. doi:10.1161/01.CIR.0000131515.03336.f8
- Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(2):168–175. doi:10.1161/01.ATV.0000051384.43104.FC
- Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. European Heart Journal. 2012;33(7):829–837. doi:10.1093/eurheartj/ehr304
- Greenland P, Blaha MJ, Budoff MJ, et al. Coronary calcium score and cardiovascular risk. Journal of the American College of Cardiology. 2018;72(4):434–447. doi:10.1016/j.jacc.2018.05.027